ESTRO 2024 - Abstract Book

S2292

Clinical - Urology

ESTRO 2024

Südharz- Klinikum Nordhausen gGmbH, Department of Radiation Oncology and Radiotherapy, Nordhausen, Germany

Purpose/Objective:

The present series analyses long-term toxicity and quality of life in patients with oligometastatic prostate cancer (OMPca) who received definitive therapy for their oligometastatic disease simultaneously with high dose IMRT for prostate cancer.

Material/Methods:

Of 971 patients who received high dose IMRT of Pca with a mean total prostate dose of 82Gy (77.4-82.8Gy) from January 2007- January 2022, 34 were oligometastatic (73% M1b; 27% M1a).

In addition to the prospective recording of toxicities (gastrointestinal (GI), genitourinary (GU)) according to the CTCAEv4.0 criteria, quality of life (QoL) was currently assessed in the OMPca group using the EORTC QLQ-C30 patient questionnaire. The follow-up period was 157(13-199) months.

Results:

The OMPca group (B) differed only insignificantly from the total group (A) with regard to GU/ GI toxicities: acute G1°/ 2°/3°/4° GU or GI toxicities occurred in 44.5%/ 2.0%/ 0.4%/0% and a maximum of 29.7%/1.3%/ 0%/0% of all patients in group A vs 41.9%/ 3.2%/ 0%/0% and 29.0%/ 0%/ 0%/0% in patients in group B, respectively. The rate of grade1/2/3/4° GU late adverse events was a maximum of 2.2%/0.8%/0%/0% (A) vs 8.3%/0%/0% (B). Grade1/2 GI late toxicities were 1.4%/0.2% (A) vs.4.2%/0% (B), higher grade GI late side effects did not occur in either group. In the assessment of the QoL function scales, patients (B) currently had mean scores of 72.2(Physical functioning)/ 73.2(Role functioning)/ 80.8(Emotional functioning)/ 84.1(Cognitive functioning)/ 81.2(Social functioning)/ 66.3(Global health status/ QoL).

QoL symptom scales were assessed as follows: 24.6(Dyspnoea)/ 21.1(Insomnia)/ 14.0(Appetite loss)/ 5.3 (Constipation)/ 5.2(Diarrhoea)/ 1.8(Financial difficulties)/ 32.6(Fatigue)/ 1.7(Nausea)/ 21.1(Pain).

Conclusion:

The results show that escalated dose IMRT of oligometastatic prostate carcinoma can be performed without a relevant increase in long-term toxicity and that the health-related quality of life of these patients does not differ from that of the age-matched general population in the long-term course.

Keywords: oligometastatic prostate cancer